Michael Deininger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12025938/publications.pdf

Version: 2024-02-01

35 papers	9,029 citations	279798 23 h-index	377865 34 g-index
35 all docs	35 docs citations	35 times ranked	7865 citing authors

#	Article	IF	Citations
1	A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine, 2012, 366, 799-807.	27.0	1,738
2	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	1.6	1,188
3	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	1.4	1,184
4	The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 2005, 105, 2640-2653.	1.4	1,137
5	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006, 108, 28-37.	1.4	1,117
6	Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 3204-3212.	1.6	458
7	The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease. Blood, 1998, 92, 3362-3367.	1.4	413
8	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. Journal of the National Cancer Institute, 2011, 103, 553-561.	6.3	362
9	Tyrosine Kinase Inhibitorâ€“Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 4210-4218.	1.6	355
10	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood, 2012, 120, 3898-3905.	1.4	154
11	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood, 2015, 126, 1551-1554.	1.4	151
12	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood, 2021, 138, 2042-2050.	1.4	95
13	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	3.5	93
14	The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 2006, 91, 452-9.	3.5	87
15	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placeboâ€controlled, Phase <scp>III</scp> study in patients with myelofibrosis. British Journal of Haematology, 2013, 161, 508-516.	2.5	83
16	Clonal Cytogenetic Abnormalities in Philadelphia Chromosome Negative Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib. Leukemia and Lymphoma, 2004, 45, 2197-2203.	1.3	71
17	Chronic Myelogenous Leukemia, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 1327-1340.	4.9	52
18	Resistance to Imatinib: Mechanisms and Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 757-768.	4.9	49

#	Article	IF	Citations
19	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 2014, 99, 292-298.	3.5	38
20	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 2022, 15, 1.	17.0	33
21	Curing CML with imatinibâ€”a dream come true?. Nature Reviews Clinical Oncology, 2011, 8, 127-128.	27.6	31
22	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leukemia Research, 2019, 79, 38-44.	0.8	25
23	Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia. Seminars in Oncology, 2008, 35, S1-S17.	2.2	23
24	Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leukemia Research, 2007, 31, 1511-1520.	0.8	15
25	Src kinases in Ph+ lymphoblastic leukemia. Nature Genetics, 2004, 36, 440-441.	21.4	14
26	Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1311-1318.	2.5	14
27	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. EBioMedicine, 2019, 50, 111-121.	6.1	14
28	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 3176-3187.	7.2	8
29	Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia. Leukemia and Lymphoma, 2008, 49, 604-609.	1.3	7
30	Clonal chromosomal abnormalities in CD34+/CD38â^' hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. Leukemia, 2010, 24, 1525-1528.	7.2	6
31	Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia and Lymphoma, 2015, 56, 1938-1948.	1.3	6
32	Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment. Leukemia Research, 2011, 35, 831-833.	0.8	4
33	High-Throughput Sequence Analysis of the Tyrosine Kinome in Acute Myeloid Leukemia.. Blood, 2007, 110, 886-886.	1.4	3
34	Various Mechanisms Underlie Cytogenetic Refractoriness to Imatinib.. Blood, 2004, 104, 2091-2091.	1.4	1
35	Tyrosine Kinase Inhibitors. , 2007, , 477-508.		0